3.82
Precedente Chiudi:
$3.98
Aprire:
$3.9
Volume 24 ore:
117.15K
Relative Volume:
0.76
Capitalizzazione di mercato:
$41.25M
Reddito:
-
Utile/perdita netta:
$-19.25M
Rapporto P/E:
-2.1461
EPS:
-1.78
Flusso di cassa netto:
$-17.87M
1 W Prestazione:
-1.80%
1M Prestazione:
-15.86%
6M Prestazione:
+9.46%
1 anno Prestazione:
+9.46%
Lantern Pharma Inc Stock (LTRN) Company Profile
Nome
Lantern Pharma Inc
Settore
Industria
Telefono
972-277-1136
Indirizzo
1920 MCKINNEY AVENUE, DALLAS, TX
Confronta LTRN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
LTRN
Lantern Pharma Inc
|
3.82 | 42.98M | 0 | -19.25M | -17.87M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
417.21 | 108.30B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
652.91 | 69.37B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.59 | 62.38B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
821.97 | 51.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.95 | 34.94B | 398.11M | -1.03B | -868.57M | -5.7032 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-10-07 | Iniziato | H.C. Wainwright | Buy |
Lantern Pharma Inc Borsa (LTRN) Ultime notizie
How Lantern Pharma Inc. stock reacts to oil pricesWeekly Loss Report & Safe Capital Growth Tips - newser.com
Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers. - BioSpace
Lantern Pharma (NASDAQ: LTRN) Reports Complete Metabolic Response in Phase 1 LP-284 Trial at LL&M Congress - Digital Journal
Will Lantern Pharma Inc. stock recover after recent dropWeekly Risk Report & Growth-Oriented Investment Plans - newser.com
Using economic indicators to assess Lantern Pharma Inc. potentialIPO Watch & Target Return Focused Picks - newser.com
Lantern Pharma (LTRN) Reports Promising Phase 1 Trial Results for LP-284 - GuruFocus
Lantern Pharma presents LP-284 clinical data at 25th LL&M Congress - MarketScreener
Is Lantern Pharma Inc. stock attractive for income investorsInsider Selling & Weekly Return Optimization Plans - newser.com
What technical signals suggest for Lantern Pharma Inc. stockGDP Growth & Growth Focused Stock Pick Reports - Fundação Cultural do Pará
Is Lantern Pharma Inc. stock a buy before product launchesTrade Volume Summary & Advanced Technical Analysis Signals - newser.com
Lantern Pharma Inc. stock trendline breakdown2025 Technical Overview & Stepwise Trade Signal Implementation - newser.com
Will Lantern Pharma Inc. stock maintain dividend yieldQuarterly Trade Summary & Real-Time Sentiment Analysis - newser.com
Why Lantern Pharma Inc. stock is favored by pension fundsTrade Exit Summary & Low Risk Profit Maximizing Plans - newser.com
Lantern Pharma’s Promising Phase II Lung Cancer Study: Key Insights for Investors - TipRanks
Lantern Pharma’s LP-284 Study: A Potential Game-Changer in Cancer Treatment? - TipRanks
Lantern Pharma’s LP-184 Study: A Potential Game-Changer in Cancer Treatment - TipRanks
When is the best time to exit Lantern Pharma Inc.July 2025 Price Swings & Free Weekly Chart Analysis and Trade Guides - newser.com
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025 - BioSpace
How to interpret RSI for Lantern Pharma Inc. stock2025 Macro Impact & AI Forecasted Stock Moves - newser.com
Lantern Pharma Inc Azioni (LTRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lantern Pharma Inc Azioni (LTRN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | 10% Owner |
Jun 13 '25 |
Sale |
3.09 |
40,000 |
123,600 |
49,957 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Kreis Leslie W. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Kreis Leslie W. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Kreis Leslie W. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Fletcher Aaron G.L. | 10% Owner |
May 27 '25 |
Sale |
3.05 |
21,037 |
64,163 |
56,467 |
| Fletcher Aaron G.L. | 10% Owner |
May 29 '25 |
Sale |
3.03 |
20,200 |
61,206 |
54,792 |
| Fletcher Aaron G.L. | 10% Owner |
May 28 '25 |
Sale |
2.87 |
15,000 |
43,050 |
55,753 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):